Protagonist Therapeutics公司近日宣布，其核心产品Rusfertide的新药申请（NDA）已正式提交至美国食品药品监督管理局（FDA）。此次提交标志着该药物在监管审批流程中迈出关键一步。
若审批进展顺利，Rusfertide有望在今年内获得上市批准并实现商业发布。这一进展对推动公司产品管线发展具有重要意义，也为相关患者群体带来新的治疗希望。
Protagonist Therapeutics公司近日宣布，其核心产品Rusfertide的新药申请（NDA）已正式提交至美国食品药品监督管理局（FDA）。此次提交标志着该药物在监管审批流程中迈出关键一步。
若审批进展顺利，Rusfertide有望在今年内获得上市批准并实现商业发布。这一进展对推动公司产品管线发展具有重要意义，也为相关患者群体带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.